全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Bioequivalence Study of Pantoprazole Sodium-HPBCD and Conventional Pantoprazole Sodium Enteric-Coated Tablet Formulations

DOI: 10.1155/2013/347457

Full-Text   Cite this paper   Add to My Lib

Abstract:

The objective of this study was to investigate the bioequivalence of two formulations of 40?mg pantoprazole sodium enteric-coated tablets: Tripepsa as the test and Pantocid as the reference. The two products were administered as a single oral dose according to a randomized two-phase crossover with a 1-month washout period in 25 healthy Indian volunteers. After drug administration, serial blood samples were collected over a period of 30 hours. Plasma pantoprazole concentrations were measured by high-performance liquid chromatography with UV detection. Pharmacokinetic parameters were analyzed based on noncompartmental analysis. The logarithmically transformed data of and were analyzed for 90% confidence intervals (CI) using ANOVA. The mean (90% CI) values for the ratio of and values of the test product over those of the reference product were 90.21 (83.69–97.24) and 108.68 (100.21–117.86), respectively (within the bioequivalence range of 80–125%). On the basis of pharmacokinetic parameters including , , and values, both the formulations were bioequivalent. 1. Introduction Pantoprazole, a proton pump inhibitor (PPI), is indicated for the treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD). Pantoprazole is one of the highly prescribed PPI in the management of peptic ulcer diseases. It shows high specificity for the relevant binding sites on activated proton pumps with little propensity to cause unwanted systemic effects [1, 2]. Pantoprazole sodium, administered as a 40?mg enteric-coated tablet, is quantitatively absorbed. Its absolute bioavailability is 77% and does not change upon multiple dosing. Following a single oral dose of 40?mg, is approximately 2.5?mg/L with a of 2-3?h. Pantoprazole is extensively metabolized in the liver and has a total serum clearance of 0.1?l/h/kg, a serum elimination half-life of about 1.1?h, and an apparent volume of distribution of 0.15?L/kg. 98% of pantoprazole is bound to serum proteins. Elimination half-life, clearance, and volume of distribution are independent of the dose. Almost 80% of an oral or intravenous dose is excreted as metabolites in urine; the remainder is found in feces and originates from biliary secretion. The clearance of pantoprazole is only slightly affected by age, with its half-life being approximately 1.25?h in the elderly [3]. Pantoprazole is an acid labile drug that requires protection from degradation in acidic media [4]. Hence, oral formulations of pantoprazole are available as enteric-coated tablets. Cyclodextrins are nonreducing cyclic oligosaccharides,

References

[1]  P. W. Jungnickel, “Pantoprazole: a new proton pump inhibitor,” Clinical Therapeutics, vol. 22, no. 11, pp. 1268–1293, 2000.
[2]  D. L. Avner, “Clinical experience with pantoprazole in gastroesophageal reflux disease,” Clinical Therapeutics, vol. 22, no. 10, pp. 1169–1185, 2000.
[3]  M. A. Pue, J. Laroche, I. Meineke, and C. de Mey, “Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects,” European Journal of Clinical Pharmacology, vol. 44, no. 6, pp. 575–578, 1993.
[4]  R. P. Raffin, L. M. Colomé, S. S. Guterres, and A. R. Pohlmann, “Enteric controlled-release pantoprazole-loaded microparticles prepared by using eudragit S100 and poly(ε-caprolactone) blend,” Pharmaceutical Development and Technology, vol. 12, no. 5, pp. 463–471, 2007.
[5]  T. Jens. Carstensen and C. T. Rhodes, Drug Stability, Principles and Practices, Marcel Dekker, New York, NY, USA, 3rd edition, 2005.
[6]  S. Yoshioka and S. J. Valentino, Stability of Drugs and Dosage Forms, Springer, Tokyo, Japan, 2002.
[7]  J. Szejtli, “Molecular encapsulation by cyclodextrins,” in Encyclopedia of Nanoscience and Nanotechnology, vol. 2, pp. 283–384, 2003.
[8]  R. Challa, A. Ahuja, J. Ali, and R. K. Khar, “Cyclodextrins in drug delivery: an updated review,” AAPS PharmSciTech, vol. 6, no. 2, pp. E329–E357, 2005.
[9]  The Unit States Pharmacopeial Convention, The United States of Pharmacopoeia—National Formulary, USP 27—NF 22, The Unit States Pharmacopeial Convention, Rockville, Md, USA, 2004.
[10]  J. Szejtli, “Past, present, and future of cyclodextrin research,” Pure and Applied Chemistry, vol. 76, no. 10, pp. 1825–1845, 2004.
[11]  T. Irie and K. Uekama, “Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation,” Journal of Pharmaceutical Sciences, vol. 86, no. 2, pp. 147–162, 1997.
[12]  S. Gould and R. C. Scott, “2-hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review,” Food and Chemical Toxicology, vol. 43, no. 10, pp. 1451–1459, 2005.
[13]  “Pantoprazole cyclodextrin inclusion complexes,” International Publication Number, W 03/059393 A1, International Publication, Patent Cooperation Treaty (PCT), 2003.
[14]  “FDA Guidance for Industry, Statistical Approaches to Establishing Bioequivalence,” US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), 2001, http://www.fda.gov/downloads/Drugs/Guidances/ucm070244.pdf.
[15]  State Committee of Pharmacopoeia, Guidance for Evaluation of Bioavailability and Bioequivalence of Pharmaceutical Preparations in Human, chapter 193, Chemical Industry Press, Beijing, China, 2005.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133